A multidisciplinary team at an academic medical center is designing a prospective, randomized, double-blind, placebo-controlled trial to evaluate a new targeted biologic therapy for refractory ulcerative colitis. The primary endpoint is the rate of clinical remission at weeks. The trial is designed with a two-sided alpha level of . A pre-study statistical analysis determines that enrolling patients per arm will provide a probability of detecting a true absolute difference in clinical remission rates of or greater between the active drug and placebo.
If the actual difference in remission rates between the biologic and placebo is indeed , what is the probability (expressed as a percentage) that the trial will incorrectly fail to demonstrate a statistically significant difference between the two groups?
Answer: 10 %